Discovery of low-molecular-weight phenylalanine derivatives as novel HIV capsid modulators with improved antiretroviral activity and metabolic stability
© 2024 Wiley Periodicals LLC..
The HIV capsid (CA) protein is a promising target for anti-AIDS treatment due to its critical involvement in viral replication. Herein, we utilized the well-documented CA inhibitor PF74 as our lead compound and designed a series of low-molecular-weight phenylalanine derivatives. Among them, compound 7t exhibited remarkable antiviral activity with a high selection index (EC50 = 0.040 µM, SI = 2815), surpassing that of PF74 (EC50 = 0.50 µM, SI = 258). Furthermore, when evaluated against the HIV-2 strain, 7t (EC50 = 0.13 µM) demonstrated approximately 14-fold higher potency than that of PF74 (EC50 = 1.76 µM). Insights obtained from surface plasmon resonance (SPR) revealed that 7t exhibited stronger target affinity to the CA hexamer and monomer in comparison to PF74. The potential interactions between 7t and the HIV-1 CA were further elucidated using molecular docking and molecular dynamics simulations, providing a plausible explanation for the enhanced target affinity with 7t over PF74. Moreover, the metabolic stability assay demonstrated that 7t (T1/2 = 77.0 min) significantly outperforms PF74 (T1/2 = 0.7 min) in human liver microsome, exhibiting an improvement factor of 110-fold. In conclusion, 7t emerges as a promising drug candidate warranting further investigation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:96 |
|---|---|
| Enthalten in: |
Journal of medical virology - 96(2024), 4 vom: 30. Apr., Seite e29594 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jiang, Xiangyi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
47E5O17Y3R |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 08.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1002/jmv.29594 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM37065739X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM37065739X | ||
| 003 | DE-627 | ||
| 005 | 20240408233045.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240405s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jmv.29594 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM37065739X | ||
| 035 | |a (NLM)38576317 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jiang, Xiangyi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Discovery of low-molecular-weight phenylalanine derivatives as novel HIV capsid modulators with improved antiretroviral activity and metabolic stability |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 Wiley Periodicals LLC. | ||
| 520 | |a The HIV capsid (CA) protein is a promising target for anti-AIDS treatment due to its critical involvement in viral replication. Herein, we utilized the well-documented CA inhibitor PF74 as our lead compound and designed a series of low-molecular-weight phenylalanine derivatives. Among them, compound 7t exhibited remarkable antiviral activity with a high selection index (EC50 = 0.040 µM, SI = 2815), surpassing that of PF74 (EC50 = 0.50 µM, SI = 258). Furthermore, when evaluated against the HIV-2 strain, 7t (EC50 = 0.13 µM) demonstrated approximately 14-fold higher potency than that of PF74 (EC50 = 1.76 µM). Insights obtained from surface plasmon resonance (SPR) revealed that 7t exhibited stronger target affinity to the CA hexamer and monomer in comparison to PF74. The potential interactions between 7t and the HIV-1 CA were further elucidated using molecular docking and molecular dynamics simulations, providing a plausible explanation for the enhanced target affinity with 7t over PF74. Moreover, the metabolic stability assay demonstrated that 7t (T1/2 = 77.0 min) significantly outperforms PF74 (T1/2 = 0.7 min) in human liver microsome, exhibiting an improvement factor of 110-fold. In conclusion, 7t emerges as a promising drug candidate warranting further investigation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a HIV‐1 | |
| 650 | 4 | |a capsid modulator | |
| 650 | 4 | |a rational drug design | |
| 650 | 4 | |a solvent‐exposed region | |
| 650 | 7 | |a Phenylalanine |2 NLM | |
| 650 | 7 | |a 47E5O17Y3R |2 NLM | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a Capsid Proteins |2 NLM | |
| 650 | 7 | |a Anti-Retroviral Agents |2 NLM | |
| 700 | 1 | |a Gao, Zhen |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Prem Prakash |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Sumit |e verfasserin |4 aut | |
| 700 | 1 | |a Rathi, Brijesh |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Xiangkai |e verfasserin |4 aut | |
| 700 | 1 | |a Dai, Jiaojiao |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Minghui |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Guanyu |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Shujing |e verfasserin |4 aut | |
| 700 | 1 | |a De Clercq, Erik |e verfasserin |4 aut | |
| 700 | 1 | |a Pannecouque, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Dick, Alexej |e verfasserin |4 aut | |
| 700 | 1 | |a Zhan, Peng |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Xinyong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical virology |d 1980 |g 96(2024), 4 vom: 30. Apr., Seite e29594 |w (DE-627)NLM000285676 |x 1096-9071 |7 nnns |
| 773 | 1 | 8 | |g volume:96 |g year:2024 |g number:4 |g day:30 |g month:04 |g pages:e29594 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jmv.29594 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 96 |j 2024 |e 4 |b 30 |c 04 |h e29594 | ||